Targeted Nanomedicines with Synergistic Chemotherapeutics to Enhance Immunotherapy of Metastatic Colorectal Cancer

靶向纳米药物与协同化疗增强转移性结直肠癌的免疫治疗

• 批准号: 10436331
• 负责人: Wenbin Lin
• 金额: $ 36.24万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10436331
• 关键词: Address; Affect; Antibodies; Antigens; Antitumor Response; Azoxymethane; Biodistribution; Biological Markers; CAR T cell therapy; CD8-Positive T-Lymphocytes; CTLA4 gene; Cancer Etiology; Cancer Vaccines; Cecum; Cell Death; Cells; Cessation of life; Chemicals; Clinical Trials; Collaborations; Colon Carcinoma; Colorectal Cancer; DNA; DNA Sequence Alteration; Dependence; Deposition; Diagnosis; Disseminated Malignant Neoplasm; Distant; Distant Metastasis; Drug Kinetics; Epidermal Growth Factor Receptor; FDA approved; Human; Immune; Immune system; Immunotherapy; Implant; In Vitro; Infiltration; Inflammatory Response; Injections; MC38; Microsatellite Instability; Microsatellite Repeats; Mismatch Repair; Modeling; Mus; Neoplasm Metastasis; Operative Surgical Procedures; Organ; PD-1 blockade; PUVA Photochemotherapy; Patients; Permeability; Phage Display; Polymers; Progression-Free Survivals; Proteins; Radiation; Rodent; Signal Transduction; Solid; Stable Disease; Survival Rate; Therapeutic; Time; Treatment Efficacy; Tumor Antigens; Tumor-infiltrating immune cells; anti-PD-L1; anti-PD-L1 antibodies; anti-PD1 antibodies; anti-cancer; anti-tumor immune response; antibody immunotherapy; base; beta catenin; biomaterial compatibility; cancer cell; cancer type; clinical translation; colon cancer patients; cytotoxic; effective therapy; exhaustion; immune activation; immune checkpoint; immune checkpoint blockade; immunogenic; immunogenic cell death; improved; in vivo; metastatic colorectal; migration; mouse model; nanocarrier; nanomedicine; nanoparticle; nanoscale; nanotherapeutic; novel; novel strategies; novel therapeutics; overexpression; oxaliplatin; particle; preclinical study; response; tumor; tumor growth

Project Summary Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the US. Over half of CRC patients have regional or distant metastasis at the time of diagnosis, and those with metastases to other organs have a 5-year survival rate of only ~12%. Checkpoint blockade immunotherapy stimulates the host immune system to generate an antitumor immune response, and has showed impressive results treating patients with mismatch repair (MMR) deficient CRC. However, up to 95% of patients with metastatic CRC (mCRC) have MMR- proficient, microsatellite-stable disease, who do not benefit from current immunotherapy. We propose to develop nanoscale coordination polymer-based targeted nanomedicines containing oxaliplatin and dihydroartemesinin (DHA), two immunogenic chemotherapeutics, for treating mCRC. EGFR-targeted nanomedicines can exert direct cytotoxic effects on CRC cells, and simultaneously induce and potentiate an antitumor immune effect. We propose the following Specific Aims in order to develop a novel combined chemotherapeutic nanomedicine and checkpoint blockade immunotherapy for the effective treatment of mCRC. Aim 1: Evaluate the mechanisms of OxPt/DHA nanoparticle anticancer efficacy on CRC cells. Aim 2: Actively target OxPt/DHA nanoparticles to CRC with an anti-EGFR Fab. Aim 3: Evaluate the anticancer efficacy of OxPt/DHA and EGFR-OxPt/DHA nanoparticles in orthotopic mouse models of CRC. Aim 4: Elucidate the immune mechanisms of antitumor response in mice treated with OxPt/DHA or EGFR-OxPt/DHA nanoparticles in combination with PD-L1 antibody. Through these aims, we seek to establish a new paradigm for the treatment of mCRC by increasing the response rate and therapeutic efficacy of immunotherapy for mCRC. Given that checkpoint blockade immunotherapies have been approved by FDA to treat multiple types of cancers, our strategy of utilizing chemotherapeutic nanomedicine as an immune system booster to potentiate checkpoint blockade can have broad impact on treating other metastatic cancers.

项目摘要 在美国，结直肠癌(CRC)是癌症相关死亡的第二大原因。 超过一半的结直肠癌患者在确诊时有区域或远处转移，以及 转移到其他器官的患者5年存活率仅为12%。检查点 阻断免疫疗法刺激宿主免疫系统产生抗肿瘤免疫 反应，并已显示出令人印象深刻的结果与错配修复(MMR)患者 CRC有缺陷。然而，高达95%的转移性结直肠癌(MCRC)患者患有MMR- 熟练的、微卫星稳定型疾病，他们不能从目前的免疫治疗中受益。我们 建议开发基于纳米配位聚合物的靶向纳米药物 奥沙利铂和双氢青蒿素(DHA)两种免疫原性化疗药物治疗 MCRC。EGFR靶向的纳米药物可以对结直肠癌细胞产生直接的细胞毒作用，并且 同时诱导和增强抗肿瘤免疫作用。我们提出以下建议 为开发一种新型的联合化疗纳米药物和 检查点阻断免疫疗法对多发性结直肠癌的有效治疗。 目的1：探讨OxPt/DHA纳米粒子对结直肠癌细胞的抗癌作用机制。 目的2：以抗EGFR Fab为靶点，将Oxpt/DHA纳米粒靶向结直肠癌。 目的3：评价OxPT/DHA纳米粒子和EGFR-OxPT/DHA纳米粒子的抗癌效果。 结直肠癌原位小鼠模型。 目的4：阐明Oxpt/DHA治疗小鼠肿瘤的免疫机制 或EGFR-Ox铂/DHA纳米颗粒与PD-L1抗体结合。 通过这些目标，我们寻求建立一种新的治疗多发性结直肠癌的范例，方法是 提高免疫治疗对多发性结直肠癌的有效率和疗效。考虑到 FDA已批准检查点封锁免疫疗法治疗多种类型的 癌症，我们利用化疗纳米药物作为免疫系统增强剂的策略 加强检查点封锁可以对其他转移性癌症的治疗产生广泛影响。